Tvardi Therapeutics
TVRD
109 hedge funds and large institutions have $18.3M invested in Tvardi Therapeutics in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 30 closing their positions.
318% more call options, than puts
Call options by funds: $46K | Put options by funds: $11K
0.13% less ownership
Funds ownership: 1.39% → 1.26% (-0.13%)
11% less funds holding
Funds holding: 122 → 109 (-13)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
43% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 30
60% less capital invested
Capital invested by funds: $45.6M → $18.3M (-$27.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$443K |
| 2 |
Two Sigma Advisers
New York
|
+$433K |
| 3 |
Morgan Stanley
New York
|
+$305K |
| 4 |
Two Sigma Investments
New York
|
+$273K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$260K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$1.63M |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$1.43M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$980K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$859K |
| 5 |
PA
Pinnacle Associates
New York
|
-$733K |
TVRD Hedge Fund Activity: Q4 2023 in Review
109 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2023, worth a combined $18.3M — down 60% from $45.6M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TVRD and 17 opened new positions — a net loss of 13 holders — while 34 trimmed existing stakes and 30 added.
The largest buyer was Renaissance Technologies, adding an estimated $443K. The largest seller was ClearBridge Investments, exiting entirely with an estimated $1.63M sold.
- 109 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2023, down from 122 in Q3 2023.
- Funds reported $18.3M of Tvardi Therapeutics stock for Q4 2023, down 60% quarter-over-quarter.
- 17 funds opened new Tvardi Therapeutics positions in Q4 2023 and 30 closed out, a net change of -13 holders.
- The largest Tvardi Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $443K added.
- The largest Tvardi Therapeutics seller in Q4 2023 was ClearBridge Investments, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2023.